{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:48:04Z","timestamp":1794044884475,"version":"4.8.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.neuropharm.2005.12.004","type":"journal-article","created":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T14:14:55Z","timestamp":1138112095000},"page":"761-768","source":"Crossref","is-referenced-by-count":41,"title":["Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat"],"prefix":"10.1016","volume":"50","author":[{"given":"Jennifer L.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenner C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2005.12.004_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0165-3806(99)00066-8","article-title":"Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain upregulated following suppression of serotonin hyperinnervation","volume":"116","author":"Basura","year":"1999","journal-title":"Brain Res. Dev. Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0169-328X(01)00151-6","article-title":"Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion","volume":"92","author":"Basura","year":"2001","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib6","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1523\/JNEUROSCI.18-14-05301.1998","article-title":"A complex program of striatal gene expression induced by dopaminergic stimulation","volume":"18","author":"Berke","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/syn.10253","article-title":"Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats","volume":"50","author":"Bishop","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0306-4522(03)00516-5","article-title":"Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats","volume":"121","author":"Bishop","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2005.03.008","article-title":"Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958","volume":"49","author":"Bishop","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib10","first-page":"167","article-title":"6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding","volume":"240","author":"Breese","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib11","first-page":"447","article-title":"Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats","volume":"234","author":"Breese","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/jpet.102.036673","article-title":"Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum","volume":"302","author":"Cai","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0306-4522(01)00218-4","article-title":"Neonatal dopamine depletion reveals a synergistic mechanism of mRNA regulation that is mediated by dopamine(D1) and serotonin(2) receptors and is targeted to tachykinin neurons of the dorsomedial striatum","volume":"105","author":"Campbell","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib15","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1523\/JNEUROSCI.0676-04.2004","article-title":"Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease","volume":"24","author":"Corvol","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0028-3908(03)00040-6","article-title":"Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907","volume":"44","author":"Dekeyne","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbr.2003.10.009","article-title":"Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias","volume":"152","author":"Delfino","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/jpet.104.068841","article-title":"Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses","volume":"310","author":"Filip","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease","volume":"15","author":"Friedman","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib22","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1523\/JNEUROSCI.22-12-05042.2002","article-title":"D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1\/2\/MAP kinase","volume":"22","author":"Gerfen","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib23","first-page":"409","article-title":"Effect of D1 and D2 agonists and antagonists on dyskinesia produced by l-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys","volume":"259","author":"Gomez-Mancilla","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0306-4522(99)00238-9","article-title":"Serotonin-2 receptor stimulation normalizes striatal preprotachykinin messenger RNA in an animal model of Parkinson's disease","volume":"93","author":"Gresch","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-328X(99)00138-2","article-title":"Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat","volume":"70","author":"Gresch","year":"1999","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.52.4.771","article-title":"D1 receptor blockade improves l-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0014-2999(85)90756-3","article-title":"Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain","volume":"111","author":"Hall","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0006-8993(90)91674-6","article-title":"Selective localization of striatal D1 receptors to striatonigral neurons","volume":"528","author":"Harrison","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0014-2999(83)90381-3","article-title":"SCH 23390 \u2013 the first selective dopamine D-1 antagonist","volume":"91","author":"Hyttel","year":"1983","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib30","first-page":"968","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0893-133X(95)00160-F","article-title":"Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats","volume":"15","author":"Kehne","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib32","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/j.1471-4159.1986.tb08506.x","article-title":"A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation","volume":"46","author":"Kilpatrick","year":"1986","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0149-7634(94)00019-W","article-title":"Dopamine receptor supersensitivity","volume":"19","author":"Kostrzewa","year":"1995","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib34","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1523\/JNEUROSCI.16-11-03727.1996","article-title":"Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons","volume":"16","author":"Laprade","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1471-4159.2000.740693.x","article-title":"Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum","volume":"74","author":"Lucas","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00002826-198610000-00010","article-title":"Open pilot trial of ritanserin in parkinsonism","volume":"9","author":"Maertens de Noordhout","year":"1986","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0022-3565(24)29546-X","article-title":"Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats","volume":"297","author":"McMahon","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib40","first-page":"262","article-title":"Controlled single-blind crossover study of ritanserin and placebo in l-DOPA-induced dyskinesias in Parkinson's disease","volume":"43","author":"Meco","year":"1988","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp.64.1.135","article-title":"Risperidone in levodopa induced dyskinesiae","volume":"64","author":"Meco","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib42","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0166-4328(96)00090-3","article-title":"Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist","volume":"73","author":"Moser","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0169-328X(95)00004-C","article-title":"Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway","volume":"29","author":"Numan","year":"1995","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","article-title":"Levodopa-induced dyskinesia: review, observations, and speculations","volume":"40","author":"Nutt","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0028-3908(89)90036-1","article-title":"Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor","volume":"28","author":"O'Boyle","year":"1989","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models","volume":"177","author":"Oh","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0091-3057(98)00240-8","article-title":"5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB","volume":"63","author":"O'Neill","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib49","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib50","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1471-4159.1992.tb10939.x","article-title":"Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease","volume":"58","author":"Pifl","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(99)00338-3","article-title":"Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats","volume":"94","author":"Pollack","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(01)00333-5","article-title":"5-HT2A and 5-HT2C\/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum","volume":"26","author":"Porras","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0006-8993(93)90995-Y","article-title":"Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study","volume":"606","author":"Radja","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib54","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archneur.58.2.249","article-title":"Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease","volume":"58","author":"Rascol","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0014-2999(92)90819-P","article-title":"5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine","volume":"223","author":"Schmidt","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib57","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1046\/j.1471-4159.1994.62041382.x","article-title":"Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine","volume":"62","author":"Schmidt","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib59","first-page":"684","article-title":"Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies","volume":"266","author":"Sorensen","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib60","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pbb.2005.06.013","article-title":"Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat","volume":"81","author":"Taylor","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib61","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/292463a0","article-title":"Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor","volume":"292","author":"Tsuruta","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2005.12.004_bib62","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(00)00175-9","article-title":"A practical synthesis of the serotonin 5-HT2A receptor antagonist MDL 100907, its enantiomer and their 3-phenolic derivatives as precursors for [11C]labeled PET ligands","volume":"8","author":"Ullrich","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2005.12.004_bib63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0091-3057(01)00552-4","article-title":"Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists","volume":"69","author":"Vickers","year":"2001","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390805004156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390805004156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T10:21:56Z","timestamp":1736245316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390805004156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0028390805004156"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2005.12.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}